Diarrhea ranks among the most common gastrointestinal side effects reported by patients starting GLP-1 therapy, affecting up to 25% of users in clinical trials
This mechanism is fundamentally different from the indirect liver benefits seen with GLP-1 single agonists, which reduce liver fat primarily through weight loss and improved insulin sensitivity
glimepiride both in combination with metformin: a randomized open Parallel-Group Study
People often notice water weight changes when they consume salty foods, experience hormonal shifts, or change their exercise routines
What we know from shorter-term studies and animal models suggests that the beneficial changes (increased Akkermansia, increased Bifidobacterium) likely persist as long as the medication continues, while the diversity reduction may stabilize or partially reverse as the gut adapts
Drug Interactions Major interactions: Non-selective MAO inhibitors (Phenelzine, Tranylcypromine) hypertensive crisis risk Increased dopaminergic effects with: Levodopa Dopamine agonists Drugs metabolized by COMT pathway may be affected (rare clinically)
